Branford, Connecticut, October 16, 2026 / PRNewswire / -- Azitra , Inc. ( NYSE American : AZTR ) Today, we announce plans to implement a reverse stock split of 1 share for 10 shares of our common stock. Azitra is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatology.

This reverse stock split will take effect at 12:01 a.m. Eastern Time on October 26, 2026. The company's common shares will continue to be traded under the symbol NYSE American with the code “AZTR”, and trading will begin based on the adjusted split ratio on October 26, 2026, at the opening of the market. After the split, the new symbol for the company's common shares will be CUSIP, with the ticker name 05479L401.

At the annual general meeting of shareholders held on June 15, 2026, the company's shareholders authorized the board of directors to amend the company's articles of association, which had been revised and restated for the second time. A reverse stock split was to be implemented at a ratio of not less than 1:2 and not more than 1:30, with the specific ratio to be determined by the board of directors. On October 14, 2026, the Azitra board of directors approved a final stock split ratio of 1:10, which took effect on October 26, 2026.

When the reverse stock split takes effect, every 10 issued common shares of the company will be automatically combined into 1 issued common share, with the par value of each share remaining unchanged. Shareholders holding shares through a brokerage account will have their holdings automatically adjusted to the new quantity after the 10-to-1 split. Shareholders who hold the company's common shares in the form of stock certificates do not need to replace their existing certificates as a result of the reverse stock split, but they may do so if they wish.

The reverse stock split will treat all shareholders equally and will not change any shareholder's percentage of ownership in the company, unless the reverse split results in shareholders holding fractional shares. No fractional shares will be issued as a result of this reverse split. Shareholders who are registered to hold such fractional shares will receive cash (without interest) in lieu of those fractional shares. The amount received will be equal to the value of those fractional shares multiplied by the average closing price of the ordinary shares during the regular trading hours of NYSE American over the five consecutive trading days prior to the effective date of the reverse split (this average closing price has been adjusted for the reverse split).

This reverse stock split will reduce the number of outstanding common shares of the company from 60,603,742 to approximately 6,060,374 shares. The number of common shares that can be exercised or converted from the company's stock options and warrants, as well as the corresponding exercise prices, will also be adjusted proportionally. Shareholders who hold shares through a brokerage account and have any questions regarding the reverse stock split should contact their brokers. All registered shareholders may contact the company's transfer agents Continental Stock Transfer & Trust Co, at the email address [email protected].

For more information regarding reverse stock splits, please refer to the final proxy statement submitted by the company to the U.S. Securities and Exchange Commission (SEC) on May 8, 2026. This document is available for free viewing at the SEC website www.sec.gov, as well as on the company's website https :// azitrainc.com.

Regarding Azitra, Inc.

Azitra, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, as well as new products covering therapeutic, cosmetic, and biotechnological applications. The company's product portfolio includes ATR-COSF, a recombinant protein technology designed for cosmetic and skincare applications, and ATR-04, a live biotherapeutic product under development for rashes related to EGFR inhibitors. Azitra has been granted Fast Track designation by the US FDA for rashes related to EGFRi; this indication affects approximately 150,000 people in the United States. Azitra is also advancing other recombinant protein projects to support biotechnological research and manufacturing applications. The company's technical platform combines engineered proteins, topical live biotherapies, artificial intelligence, and a proprietary microbiome library, aiming to develop differentiated products for consumer, research, and medical markets. For more information, please visit https:// azitrainc.com.

Forward-looking Statements Warning

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 and its amendments. These statements can be identified by the use of the phrases “aims”, “anticipates”, “believes”, “could”, “estimates”, “expects”, “forecasts”, “goal”, “intends”, “may”, “plans”, “possible”, “potential”, “seeks”, “will”, “would”, “target”, “continue”, “ongoing”, and their variations, or similar expressions. Except for statements of historical fact, any such statements in this press release may be considered forward-looking statements. Such forward-looking statements include, but are not limited to: (i) the potential impact of a reverse stock split on the company's common stock price; (ii) whether the securities will be able to continue to be listed under NYSE American; and (iii) statements regarding the company's clinical and pre-clinical projects, as well as the company's clinical/pre-clinical strategies, including its cosmetic and dermatological strategies.

Please do not rely excessively on any forward-looking statements. The forward-looking statements in this press release are based solely on current expectations, estimates, and projections as of the date of issuance and are subject to various risks and uncertainties that may result in material differences between actual results and those implied or stated in these forward-looking statements. These risks and uncertainties include, but are not limited to: the timing and outcomes of clinical trials; potential delays in enrollment; possible delays in providing initial or additional safety data for ATR-04 (if applicable) and top-line results, which, if they occur, may not be positively evaluated; the safety and effectiveness of our product candidates; delays in regulatory approval or changes in the regulatory framework beyond our control; possible inaccuracies in our estimates of the market size that our product candidates can serve; our inability to raise the additional funds required in a timely manner; the emergence of more efficient competitors or more effective competitive therapies; potential involvement in disputes regarding the use of intellectual property, which is crucial to our success; our inability to attract and retain key employees and qualified personnel; the fact that earlier research results may not predict later study outcomes; and our reliance on third parties for part or all of product manufacturing, research, and preclinical and clinical testing. Additional risks related to the Azitra project and operations are disclosed or incorporated by reference in the company's 10-K annual report filed with the SEC on February 27, 2026, and the 10-Q quarterly report filed with the SEC on August 12, 2026. The company hereby declares that, except as required by law, it has no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this press release.

Contact Information

Norman Staskey

Investor Relations

Media Relations